or Try an Advanced Search...

    Technical Analysis for SCLX - Scilex Holding Company

    Grade Last Price % Change Price Change
    C 1.88 -2.59% -0.05
    SCLX closed down 2.59 percent on Monday, July 1, 2024, on 76 percent of normal volume.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Up
    Historical SCLX trend table...
    Date Alert Name Type % Chg
    Wide Bands Range Expansion 0.00%
    Wide Bands Range Expansion -2.59%
    Up 3 Days in a Row Strength -2.59%
    Gapped Down Weakness -2.59%
    Wide Bands Range Expansion 5.03%
    Crossed Above 200 DMA Bullish 25.33%
    Calm After Storm Range Contraction 25.33%
    NR7 Range Contraction 25.33%
    Narrow Range Bar Range Contraction 25.33%
    Wide Bands Range Expansion 25.33%
    Older End-of-Day Signals for SCLX ...

       Recent Intraday Alerts

    Alert Time
    10 DMA Support about 6 hours ago
    Down 5% about 6 hours ago
    Down 3% about 6 hours ago
    Down 2 % about 6 hours ago
    Down 1% about 6 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    SCLX Chart by TradingView
    Basic chart:

    Profile

    • Earnings date: Unknown
    Scilex Holding Company Description

    Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Scilex is uncompromising in its focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life. Results from the Phase III Pivotal Trial C.L.E.A.R Program for SEMDEXA™, its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with moderate to severe pain.

    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - General
    Keywords: Organ Systems Pain Pharmaceutical Products Chronic Pain Opioids Pain Management Acute Pain Acute And Chronic Pain Palliative Care Nociception

    Is SCLX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 20 Scilex Holding Company Partners with New National Distributor, Endeavor Distribution LLC.
    Jun 14 Scilex Holding Company Announces Publication in PAIN Journal Regarding Phase 3 Results of the Pivotal Registration Trial of SP-102 (SEMDEXA™) in Lumbosacral Radicular Pain (Sciatica)
    Jun 14 Scilex Holding Company (NASDAQ:SCLX) Analysts Just Cut Their EPS Forecasts Substantially
    Jun 13 Scilex Holding Company to Present Poster on ELYXYB® (celecoxib oral solution) at the 66th Annual Scientific Meeting of the American Headache Society (AHS) to be Held in San Diego, CA on June 13-16, 2024
    Jun 11 Scilex Holding Company Announces 5-Year Term of $100 Million Financing with Royalty-Based Payments and Potential Strategic Transactions with Perigrove and its Portfolio Companies
    Jun 11 SCLX: Undervalued and Adding Products
    Jun 11 Scilex Holding Company Announces That Many National Pharmacy Chains and Independent Pharmacies Have Begun Stocking GLOPERBA®
    Jun 10 Scilex Holding Company Announces Stocking of GLOPERBA® is Underway in all of the Wholesalers with which Scilex has Stocking Arrangements Throughout the U.S.
    Jun 6 Scilex gains FDA approval for liquid version of colchine for gout flares
    Jun 6 Scilex Holding Company announces the U.S. FDA has approved the sNDA for commercial manufacturing of Gloperba® which will be launched in the US in the week of June 10th 2024
    See more SCLX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 6.55
    52 Week Low 0.7316
    Average Volume 1,153,513
    200-Day Moving Average 1.47
    50-Day Moving Average 1.18
    20-Day Moving Average 1.53
    10-Day Moving Average 1.81
    Average True Range 0.20
    RSI (14) 61.39
    ADX 45.64
    +DI 35.22
    -DI 13.05
    Chandelier Exit (Long, 3 ATRs) 1.69
    Chandelier Exit (Short, 3 ATRs) 1.66
    Upper Bollinger Bands 2.20
    Lower Bollinger Band 0.86
    Percent B (%b) 0.76
    BandWidth 87.87
    MACD Line 0.19
    MACD Signal Line 0.17
    MACD Histogram 0.0151
    Fundamentals Value
    Market Cap 296.86 Million
    Num Shares 158 Million
    EPS -1.16
    Price-to-Earnings (P/E) Ratio -1.62
    Price-to-Sales 5.73
    Price-to-Book 28.85
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.11
    Resistance 3 (R3) 2.10 2.03 2.07
    Resistance 2 (R2) 2.03 1.97 2.03 2.05
    Resistance 1 (R1) 1.95 1.93 1.92 1.96 2.04
    Pivot Point 1.88 1.88 1.86 1.88 1.88
    Support 1 (S1) 1.80 1.82 1.77 1.81 1.72
    Support 2 (S2) 1.73 1.78 1.73 1.71
    Support 3 (S3) 1.65 1.73 1.69
    Support 4 (S4) 1.66